We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The antiviral reduced the risk for severe symptoms of ...

People with acute COVID-19 who took the antiviral drug molnupiravir (Lagevrio) reported modest improvements in symptoms, less time off from work or study, and less healthcare utilization at 6 months ...

The antiviral drug molnupiravir (Lagevrio) slashed the risk of death from COVID-19 in half when given early to older adults. It also lowered all-cause deaths among older adults in the Czech Republic ...

A recent study published in JAMA Network Open examined the efficacy of nirmatrelvir-ritonavir and molnupiravir in non-hospitalized patients with coronavirus disease 2019 (COVID-19) and type 2 diabetes ...

In patients hospitalized with COVID-19, adding molnupiravir or nirmatrelvir-ritonavir to usual care was not associated with improved clinical outcomes, including 28-day mortality duration of hospital ...

"Molnupiravir administered at human effect size-equivalent dose blocks SARS-CoV-2 transmission in ferrets, researchers find." ScienceDaily. www.sciencedaily.com / releases / 2023 / 08 / ...

There are currently two approved COVID-19 treatments that can be taken orally: nirmatrelvir-ritonavir (known as Paxlovid and developed by Pfizer) and Merck’s molnupiravir. They have both been shown to ...

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has ...

Oral outpatient treatment for Covid-19 is needed. In this phase 3, double-blind, randomized, controlled trial, molnupiravir, a small-molecule antiviral, was studied in unvaccinated patients with less ...

ATLANTA—Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/ritonavir), provide equivalent therapeutic benefit in preventing severe COVID-19 in animal models ...